In a double-blind clinical trial with 20 patients suffering from
endogenous depression statistically significant changes (improvement) were present in the scores of all assessment instruments. Although no statistically significant differences occurred between the groups, significant improvement on the HAM-D occurred earlier for
amitriptyline and significant improvement occurred earlier on HAM-A for
viloxazine. 2 patients were discontinued due to adverse reactions; one for
nausea and
vomiting while receiving
viloxazine and one for paroxysmal atrial
tachycardia while receiving
amitriptyline. The same number of
TES occurred for each group with seven unique to
viloxazine (
numbness, tingling, palpitation, ejaculation difficulty,
nausea/
vomiting,
diarrhea, epigastric
pain and gustatory disturbances) and seven unique to
amitriptyline (
insomnia, irritability,
syncope,
tremor, nasal congestion, orthostatic
hypertension and paroxysmal atrial
tachycardia). Other than for 1 patient who developed
syncope and
orthostatic hypotension and the patient who developed paroxysmal atrial
tachycardia, there were no clinically significant changes in pulse rate, blood pressure and weight. There were no clinical laboratory findings with either
drug that were judged to be pathological.